NEUROLOGIE PRO PRAXI / Neurol. praxi. 2024;25(1):53-56 / www.neurologiepropraxi.cz 56 PŘEHLEDOVÉ ČLÁNKY Ocrelizumab – co víme, co můžeme zlepšit nyní a co v budoucnu on in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. J Neurol. 2022;269(10):5443-5453. 8. Hartung HP, Berger T, Bermel R, et al. Shorter infusion time of ocrelizumab: Results from the randomized, double‑blind ENSEMBLE PLUS substudy in patients with relapsing‑remitting multiple sclerosis. Mult Scler Relat Disord. 2020;46:102492. 9. Hauser SL, Bar‑Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. 10. Hauser SL, Bar‑Or A, Weber MS, et al. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurol-Neuroimmunol Neuroinflamma‑ tion. 2023;10(2):e200094. 11. He A, Merkel B, Brown JWL, et al. Timing of high‑efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. 12. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse‑Independent Progression vs Relapse‑Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. Jama Neurol. 2020;77(9):1132-1140. 13. Kempen ZL van, Hogenboom L, Killestein J. Stable multiple sclerosis patients on anti‑CD20 therapy should go on extended interval dosing: NO. Mult Scler J. 2022;28(5):693-695. 14. Kister I, Oh C, Douglas EA, et al. No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis. Neurol: Clin Pr. 2023;13(5):e200185. 15. Montalban X, Matthews PM, Simpson A, et al. Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review. Ann Clin Transl Neurol. 2023;10(3):302-311. 16. Pfeuffer S, Rolfes L, Ingwersen J, et al. Effect of Previous Disease‑Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. Neurology Neuroimmunol Neuroinflammation. 2023;10(3):e200104. 17. Song A, Hendricks R, Chung S, et al. Immunogenicity with Repeated Dosing of Ocrelizumab in Patients with Multiple Sclerosis (P2.087) Neurology Apr 2016, 86 (16 Supplement) P2.087. Avalilable form: htps://n.neurology.org/content/86/16_Supplement/P2.087. 18. Toorop AA, Lierop ZYGJ van, Strijbis EMM, et al. The wearing‑off phenomenon of ocrelizumab in patients with multiple sclerosis. Mult Scler Relat, DiS. 2022;57:103364. 19. Torres J, Roodselaar J, Sealey M, et al. Distribution and Efficacy of Ofatumumab and Ocrelizumab in Humanized CD20 Mice Following Subcutaneous and Intravenous Administration. Front Immunol. 2022;13:814064. 20. Vermersch P, Oreja‐Guevara C, Siva A, et al. Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3 b CASTING single‐arm, open‐label trial. Eur J Neu‑ rol. 2022;29(3):790-801. 21. Zecca C, Bovis F, Novi G, et al. Treatment of multiple sclerosis with rituximab: a multicentric Italian–Swiss experience. Mult Scler J. 2019;26(12):1519-1531. 3. 4. 10. 2024 ÚSTÍ NAD LABEM 4. dny praktické neurologie VÍCE INFORMACÍ NA www.kongresneurologie.cz
RkJQdWJsaXNoZXIy NDA4Mjc=